DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 12-940/S-044

Wyeth-Ayerst
Attention: Ms. Mary Alice Dankulich
150-B3 North Radnor Chester Road
St. Davids, PA 19087

Dear Ms. Dankulich:

Please refer to your supplemental new drug application dated August 24, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Isordil Sublingual (isosorbide dinitrate) 2.5, 5 and 10 mg Tablets.

We acknowledge receipt of your submission dated August 9, 2001 that constituted a complete response to our March 23, 2001 approvable letter.

This supplemental new drug application provides for final printed labeling revised as follows:

1. Under **PRECAUTIONS**, a **Geriatric Use** subsection has been added that reads as follows:

   Clinical studies of Isordil (isosorbide dinitrate) Sublingual did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

2. A "Rx Only" statement has been added above the **DESCRIPTION** section.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted final printed labeling (package insert included in your submission of August 9, 2001). Accordingly, the supplemental application is approved effective on the date of this letter.

Please capitalize, at your next printing, the phrase "**Clinical Pharmacology**" in the first sentence of the **DOSAGE AND ADMINISTRATION** section.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact:

Mr. Edward Fromm
Regulatory Health Project Manager
(301) 594-5313

Sincerely,

{See appended electronic signature page}

Raymond J. Lipicky, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Raymond Lipicky
9/16/01 12:10:04 PM